Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

ALLERGAN PLC (AGN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Allergan : Allergans Botox gets US FDA green light to treat forehead lines

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/04/2017 | 04:15pm CET

Allergan PLC (NYSE:AGN) has received the US Food and Drug Administration (FDA) approval for the use of Botox for the temporary improvement of moderate-to-severe forehead lines.

The latest approval makes the brand the first and only neurotoxin to be indicated for three facial treatment areas. It has already been approved for the treatment of "crow`s feet" and glabellar lines.

In a statement released today announcing the FDA approval, David Nicholson, the companys chief research and development officer said: Allergan recognizes that forehead lines are a top area of concern for patients.

(c) 2017 TBREAK MEDIA. ALL RIGHTS RESERVED. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALLERGAN PLC
01/22 WILLIAM ACKMAN : Ackman cuts staff, shuns limelight as he seeks to turn around f..
01/20 ALLERGAN : Factory Mutual Insurance Co. Increases Holdings in Allergan plc (AGN)
01/19 AMGEN : EC approves Amgen's biosimilar Avastin
01/18 ALLERGAN : European Commission Approves Amgen And Allergan's MVASI® (Biosimilar ..
01/17 Ironwood and Allergan Announce Settlement with Sun Pharma Resolving LINZESS P..
01/17 Allergan Pact Advances -- WSJ
01/17 Judge Signals He Will Approve $290 Million Settlement Between Allergan Shareh..
01/16 Judge Signals He Will Approve $290 Million Settlement Between Allergan Shareh..
01/16 ALLERGAN : Ironwood and Allergan Announce Settlement with Sun Pharma Resolving L..
01/13 ALLERGAN : Evolus Files for IPO Ahead of Potential 2018 Approval for Botox Alter..
More news
News from SeekingAlpha
01/21 Top 10 Net Payout Yields For January 2018
01/20 YOUR DAILY PHARMA SCOOP : Ablynx Takeover Battle, Acorda Takeover Speculation, O..
01/18 EC OKs Amgen's Avastin biosimilar
01/18 Big Biopharma in the red in early trade
01/16 ALLERGAN : Insiders Buy; Investors Shy Away
Financials ($)
Sales 2017 15 892 M
EBIT 2017 7 624 M
Net income 2017 -6 499 M
Debt 2017 24 894 M
Yield 2017 1,58%
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 5,36x
EV / Sales 2018 5,45x
Capitalization 60 307 M
Chart ALLERGAN PLC
Duration : Period :
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 217 $
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Maria Teresa Hilado Chief Financial Officer
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
James H. Bloem Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC10.85%60 307
JOHNSON & JOHNSON5.47%395 886
NOVARTIS1.19%227 592
PFIZER1.99%220 189
ROCHE HOLDING LTD.-4.87%211 135
MERCK AND COMPANY8.90%167 132